HER-2 gene amplification by fluorescence in situ hybridization (FISH) compared with immunohistochemistry (IHC) in breast cancer: a study of 528 equivocal cases

被引：16
作者：
Zhang, Han [1 ]
Ren, Guoping [1 ]
Wang, Xiaoling [1 ]
Zhao, Jing [1 ]
Yao, Hongtian [1 ]
Bai, Yanfeng [1 ]
Bo, Wang [1 ]
机构：
[1] Zhejiang Univ, Dept Pathol, Affiliated Hosp 1, Hangzhou 310003, Zhejiang, Peoples R China
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2012年 / 134卷 / 02期
基金：
匈牙利科学研究基金会;
关键词：
Breast cancer; Fluorescence in situ hybridization; HER-2/neu; PROGESTERONE-RECEPTOR GENE; INTEROBSERVER REPRODUCIBILITY; PROTEIN OVEREXPRESSION; ESTROGEN; EXPRESSION; ANEUSOMY; TISSUE;
D O I：
10.1007/s10549-012-2101-x
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The concordance rate between fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) on evaluating HER-2/neu status is still controversial, especially for the IHC 2+/equivocal cases. In this study, we investigated the amplification of HER-2/neu gene by FISH in IHC (2+)/equivocal specimens to clarify the correlation between HER-2/neu and clinicopathologic features of breast cancers. HER-2/neu amplification was determined by FISH on 528 specimens of breast carcinomas with equivocal expression of HER-2/neu protein by IHC detection. 65.5 % of IHC 2+ patients were negative for HER-2/neu amplification, 29.0 % were positive and the remaining was equivocal. A statistically significant inverse association was found between hormone receptor expression and HER-2/neu amplification (P < 0.05). Furthermore, polysomy of CEP17 was detected in 60 % of breast carcinomas. The results highlight the necessity of FISH test for further categorization when breast carcinoma cases are scored 2+ by IHC.
引用
收藏
页码：743 / 749
页数：7
相关论文
共 30 条
  • [21] RUSSELL KS, 1992, CANCER RES, V52, P6624
  • [22] Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations
    Sauter, Guido
    Lee, James
    Bartlett, John M. S.
    Slamon, Dennis J.
    Press, Michael F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (08) : 1323 - 1333
  • [23] HUMAN-BREAST CANCER - CORRELATION OF RELAPSE AND SURVIVAL WITH AMPLIFICATION OF THE HER-2 NEU ONCOGENE
    SLAMON, DJ
    CLARK, GM
    WONG, SG
    LEVIN, WJ
    ULLRICH, A
    MCGUIRE, WL
    [J]. SCIENCE, 1987, 235 (4785) : 177 - 182
  • [24] Tsuda H, 2001, CANCER-AM CANCER SOC, V92, P2965, DOI 10.1002/1097-0142(20011215)92:12<2965::AID-CNCR10156>3.0.CO
  • [25] 2-A
  • [26] Immunohistochemical determination of HER-2/neu expression in invasive breast carcinoma
    Vang, R
    Cooley, LD
    Harrison, WR
    Reese, T
    Abrams, J
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2000, 113 (05) : 669 - 674
  • [27] Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma
    Watters, AD
    Going, JJ
    Cooke, TG
    Bartlett, JMS
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2003, 77 (02) : 109 - 114
  • [28] American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
    Wolff, Antonio C.
    Hammond, M. Elizabeth H.
    Schwartz, Jared N.
    Hagerty, Karen L.
    Allred, D. Craig
    Cote, Richard J.
    Dowsett, Mitchell
    Fitzgibbons, Patrick L.
    Hanna, Wedad M.
    Langer, Amy
    McShane, Lisa M.
    Paik, Soonmyung
    Pegram, Mark D.
    Perez, Edith A.
    Press, Michael F.
    Rhodes, Anthony
    Sturgeon, Catharine
    Taube, Sheila E.
    Tubbs, Raymond
    Vance, Gail H.
    de Vijver, Marc Van
    Wheeler, Thomas M.
    Hayes, Daniel F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (01) : 118 - 145
  • [29] HER-2 testing in breast cancer using parallel tissue-based methods
    Yaziji, H
    Goldstein, LC
    Barry, TS
    Werling, R
    Hwang, H
    Ellis, GK
    Gralow, JR
    Livingston, RB
    Gown, AM
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (16): : 1972 - 1977
  • [30] Yosepovich A, 2010, ISR MED ASSOC J, V12, P353
123